Brief: Shield Therapeutics Says ACCRUFeR Assigned Priority Review In US By FDA
04/09/2025 08:02
Sept 4 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS - ACCRUFER® ASSIGNED PRIORITY REVIEW IN US BY FDA SHIELD THERAPEUTICS PLC - ACCRUFER® APPROVAL IN US ANTICIPATED IN 2026 Source text: ID:nRSD9329Xa Further company coverage: STXS.L ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update